News
The study in healthy human subjects is expected to help the company determine the best path forward in Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress ...
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ...
Home News GlobeNewswire Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital ...
Shares of Alzamend Neuro nearly doubled after the biopharmaceutical company said it dosed the first patient in a Phase II clinical trial for its "lithium in brain" study. Shares were up 99% to $6. ...
The capital raised will be used to support the five Phase II clinical trials of AL001 “Lithium in Brain” Studies at Massachusetts General Hospital. The first trial, in healthy human subjects ...
A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, more powerful drugs for cognition and behavior.
“The dosing of the first patient in our first Phase II trial of AL001 is another significant step forward in our goal to introduce a next-generation lithium treatment that offers enhanced safety ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results